Mayo team spot­lights the role of senes­cent cells in neu­rode­gen­er­a­tion, start­ing down a path­way that may lead to Alzheimer’s

As an­ti-ag­ing re­search grows around the world, there’s been a big fo­cus on clear­ing away the “senes­cent” cells that clut­ter bod­ies as peo­ple grow old­er. These ag­ing cells lose the abil­i­ty to di­vide and mouse stud­ies have of­fered a pre­clin­i­cal the­o­ry that sweep­ing them away with new drugs can of­fer peo­ple longer, health­i­er lives.

Now a re­search team at the Mayo Clin­ic is of­fer­ing more an­i­mal da­ta to back that up, and they’re shin­ing a light on a new path­way in neu­rode­gen­er­a­tion and specif­i­cal­ly Parkin­son’s and Alzheimer’s — per­haps the sin­gle most frus­trat­ing field in drug de­vel­op­ment.

Ac­cord­ing to the Mayo team, they were able to de­ter­mine that mi­croglia and as­tro­cyte cells were most like­ly to turn in­to rogue zom­bies. By clear­ing these senes­cent cells from the brains of mice, they tar­get­ed a key path­way im­pli­cat­ed in Alzheimer’s, tamped down on in­flam­ma­tion and had an im­pact on mem­o­ry.

“We used a mouse mod­el that pro­duces sticky, cob­web like tan­gles of tau pro­tein in neu­rons and has ge­net­ic mod­i­fi­ca­tions to al­low for senes­cent cell elim­i­na­tion,” ex­plains first au­thor Tyler Buss­ian, a Mayo Clin­ic Grad­u­ate School of Bio­med­ical Sci­ences stu­dent. “When senes­cent cells were re­moved, we found that the dis­eased an­i­mals re­tained the abil­i­ty to form mem­o­ries, elim­i­nat­ed signs of in­flam­ma­tion, did not de­vel­op neu­rofib­ril­lary tan­gles, and had main­tained nor­mal brain mass.”

The work was pub­lished in Na­ture.

It’s a big leap — and an in­cred­i­bly com­plex chal­lenge — to go from a dis­ease mod­el in pre­clin­i­cal stud­ies to test­ing this con­cept in hu­mans. But bil­lions have been spent on Alzheimer’s with noth­ing but fail­ure to show for it. The theme now is try­ing new things, with a bet­ter un­der­stand­ing that bend­ing the curve of neu­rode­gen­er­a­tion in pa­tients who ex­hib­it symp­toms of their dis­ease will be ex­tra­or­di­nar­i­ly dif­fi­cult.

The most ad­vanced biotech in the senes­cence field is an up­start called Uni­ty, which was able to trans­late their pre­clin­i­cal work in­to a Phase I which starts with os­teoarthri­tis. But in­ves­ti­ga­tors in the field — in­clud­ing the team at Uni­ty — be­lieve they’re on a trail that leads to a host of ail­ments.

Alzheimer’s just may be one of them.

Im­age: Dar­ren Bak­er, se­nior au­thor, and Tyler Buss­ian.MAYO CLIN­IC

M&A: a crit­i­cal dri­ver for sus­tain­able top-line growth in health­care

2021 saw a record $600B in healthcare M&A activity. In 2022, there is an anticipated slowdown in activity, however, M&A prospects remain strong in the medium to long-term. What are future growth drivers for the healthcare sector? Where might we see innovations that drive M&A? RBC’s Andrew Callaway, Global Head, Healthcare Investment Banking discusses with Vito Sperduto, Global Co-Head, M&A.

Abortion-rights protesters regroup and protest following Supreme Court's decision to overturn Roe v. Wade. (AP Photo/Gemunu Amarasinghe)

Fol­low­ing SCO­TUS de­ci­sion to over­turn abor­tion pro­tec­tions, AG Gar­land says states can't ban the abor­tion pill

Following the Supreme Court’s historic decision on Friday to overturn Americans’ constitutional right to an abortion after almost 50 years, Attorney General Merrick Garland sought to somewhat reassure women that states will not be able to ban the prescription drug sometimes used for abortions.

Following the decision, the New England Journal of Medicine also published an editorial strongly condemning the reversal, saying it “serves American families poorly, putting their health, safety, finances, and futures at risk.”

AstraZeneca's new Evusheld direct to consumer campaign aims to reach more immunocompromised patients.

As­traZeneca de­buts first con­sumer cam­paign for its Covid-19 pro­phy­lac­tic Evusheld — and a first for EUA drugs

AstraZeneca’s first consumer ad for Evusheld is also a first for drugs that have been granted emergency use authorizations during the pandemic.

The first DTC ad for a medicine under emergency approval, the Evusheld campaign launching this week aims to raise awareness among immunocompromised patients — and spur more use.

Evusheld nabbed emergency authorization in December, however, despite millions of immunocompromised people looking for a solution and now more widespread availability of the drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

De­spite a slow start to the year for deals, PwC pre­dicts a flur­ry of ac­tiv­i­ty com­ing up

Despite whispers of a busy year for M&A, deal activity in the pharma space is actually down 30% on a semi-annualized basis, according to PwC’s latest report on deal activity. But don’t rule out larger deals in the second half of the year, the consultants said.

PwC pharmaceutical and life sciences consulting solutions leader Glenn Hunzinger expects to see Big Pharma companies picking up earlier stage companies to try and fill pipeline gaps ahead of a slew of big patent cliffs. Though a bear market continues to maul the biotech sector, Hunzinger said recent deals indicate that pharma companies are still paying above current trading prices.

Joe Wiley, Amryt Pharma CEO

Am­ryt Phar­ma sub­mits a for­mal dis­pute res­o­lu­tion to the FDA over re­ject­ed skin dis­ease drug

The story of Amryt Pharma’s candidate for the genetic skin condition epidermolysis bullosa, or EB, will soon enter another chapter.

After the Irish drugmaker’s candidate, dubbed Oleogel-S10 and marketed as Filsuvez, was handed a CRL earlier this year, the company announced in a press release that it plans to submit a formal dispute resolution request for the company’s NDA for Oleogel-S10.

Sen. Thom Tillis (R-NC) (J. Scott Applewhite/AP Images)

Phar­ma-friend­ly sen­a­tor calls on FDA for a third time to show patent pro­tec­tions should­n't be blamed for high drug prices

North Carolina Republican Sen. Thom Tillis made a name for himself in the 2020 election cycle as the darling of the pharma industry, accepting hundreds of thousands in campaign contributions, even from the likes of Pfizer CEO Albert Bourla.

Those contributions have led Tillis to attempt to re-write patent laws in pharma’s favor, a move which failed to gain steam in 2019, and request for a third time since January that the FDA should help stop “the false narrative that patent protections are to blame for high drug prices.”

EMA signs off on 3 drugs re­cent­ly re­ject­ed by FDA, in­clud­ing Bio­Mar­in's new he­mo­phil­ia gene ther­a­py

The EMA’s human medicines committee on Friday recommended three new drugs for approval or conditional approval, even as their US counterparts have rejected these three for various reasons.

In a major move, CHMP offered a thumbs-up to a conditional marketing authorization for the first gene therapy to treat severe hemophilia A, although the agency cautioned that it’s so far unknown how long the effects of infusion will last.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

Joe Papa (Ryan Remiorz/The Canadian Press via AP, File)

Joe Pa­pa re­signs as chair of Bausch Health as bil­lion­aire John Paul­son takes over

Joe Papa, chair of Bausch Health, officially resigned on Thursday and the board appointed billionaire hedge fund manager John Paulson as the new chair, effective immediately.

The specialty pharma company sought to make clear that Papa’s abrupt departure “was not due to any dispute or disagreement with the Company, its management or the Board on any matter relating to the Company’s operations, policies or practices.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

Yong Dai, Frontera Therapeutics CEO

Scoop: Lit­tle-known Or­biMed-backed biotech clos­es $160M round to start gene ther­a­py tri­al

Frontera Therapeutics, a China and US biotech, has closed a $160 million Series B and received regulatory clearance to test its first gene therapy stateside, Endpoints News has learned.

Led by the largest shareholder, OrbiMed, the biotech has secured $195 million total since its September 2019 founding, according to an email reviewed by Endpoints. The lead AAV gene therapy program is for an undisclosed rare eye disease, according to the source.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.